A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma.

Shetal A Patel,Michael K Gibson,Allison Deal,Siddharth Sheth,Hilary Heiling,Steven M Johnson,Kathe Douglas,Melissa Flores,Jeffrey Blumberg,Catherine Lumley,Wendell G Yarbrough,Colette Shen,Bhishamjit S Chera,Jessica R Bauman,Trevor Hackman,Jared Weiss

Cancer（2023）

引用 0|浏览44

暂无评分

摘要

Neoadjuvant carboplatin, nab-paclitaxel, and durvalumab before surgical resection of HNSCC were safe and feasible. Although the primary end point was not met, encouraging rates of pathologic complete response and clinical to pathologic downstaging were observed.

查看译文

关键词

durvalumab, head and neck cancer, neoadjuvant chemo-immunotherapy, oral cavity, oropharynx

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要